524 related articles for article (PubMed ID: 26413978)
1. Genetics of pancreatic neuroendocrine tumors: implications for the clinic.
Pea A; Hruban RH; Wood LD
Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978
[TBL] [Abstract][Full Text] [Related]
2. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.
Hackeng WM; Brosens LA; Poruk KE; Noë M; Hosoda W; Poling JS; Rizzo A; Campbell-Thompson M; Atkinson MA; Konukiewitz B; Klöppel G; Heaphy CM; Meeker AK; Wood LD
Hum Pathol; 2016 Oct; 56():93-100. PubMed ID: 27342911
[TBL] [Abstract][Full Text] [Related]
3. Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression.
Martin DR; LaBauve E; Pomo JM; Chiu VK; Hanson JA; Gullapalli RR
Pancreas; 2018 Apr; 47(4):502-510. PubMed ID: 29521944
[TBL] [Abstract][Full Text] [Related]
4. Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.
Roy S; LaFramboise WA; Liu TC; Cao D; Luvison A; Miller C; Lyons MA; O'Sullivan RJ; Zureikat AH; Hogg ME; Tsung A; Lee KK; Bahary N; Brand RE; Chennat JS; Fasanella KE; McGrath K; Nikiforova MN; Papachristou GI; Slivka A; Zeh HJ; Singhi AD
Gastroenterology; 2018 Jun; 154(8):2060-2063.e8. PubMed ID: 29486199
[TBL] [Abstract][Full Text] [Related]
5. New Genetics and Genomic Data on Pancreatic Neuroendocrine Tumors: Implications for Diagnosis, Treatment, and Targeted Therapies.
Schmitt AM; Marinoni I; Blank A; Perren A
Endocr Pathol; 2016 Sep; 27(3):200-4. PubMed ID: 27456058
[TBL] [Abstract][Full Text] [Related]
6. Molecular Characterization and Treatment of Pancreatic Neuroendocrine Tumors.
De Jesus-Acosta AMC
Oncology (Williston Park); 2019 Dec; 33(12):. PubMed ID: 31914198
[No Abstract] [Full Text] [Related]
7. [What is new in the pathology of pancreatic neuroendocrine tumors?].
Komminoth P; Perren A
Pathologe; 2015 May; 36(3):220-8. PubMed ID: 25941099
[TBL] [Abstract][Full Text] [Related]
8. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
[No Abstract] [Full Text] [Related]
9. Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?
Luchini C; Lawlor RT; Bersani S; Vicentini C; Paolino G; Mattiolo P; Pea A; Cingarlini S; Milella M; Scarpa A
Curr Oncol Rep; 2021 Jul; 23(9):106. PubMed ID: 34269919
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic Neuroendocrine Neoplasms: Landscape and Horizon.
Tang LH
Arch Pathol Lab Med; 2020 Jul; 144(7):816-828. PubMed ID: 32298138
[TBL] [Abstract][Full Text] [Related]
11. Pathologic Classification of Neuroendocrine Neoplasms.
Klimstra DS
Hematol Oncol Clin North Am; 2016 Feb; 30(1):1-19. PubMed ID: 26614366
[TBL] [Abstract][Full Text] [Related]
12. Genomic landscape of pancreatic neuroendocrine tumors.
Gebauer N; Schmidt-Werthern C; Bernard V; Feller AC; Keck T; Begum N; Rades D; Lehnert H; Brabant G; Thorns C
World J Gastroenterol; 2014 Dec; 20(46):17498-506. PubMed ID: 25516664
[TBL] [Abstract][Full Text] [Related]
13. Advancements in pancreatic neuroendocrine tumors.
Sadaria MR; Hruban RH; Edil BH
Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5):477-90. PubMed ID: 23899286
[TBL] [Abstract][Full Text] [Related]
14. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy.
de Wilde RF; Edil BH; Hruban RH; Maitra A
Nat Rev Gastroenterol Hepatol; 2012 Feb; 9(4):199-208. PubMed ID: 22310917
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic neuroendocrine tumors: pathologic and molecular characteristics.
Shi C; Klimstra DS
Semin Diagn Pathol; 2014 Nov; 31(6):498-511. PubMed ID: 25441311
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors.
Dreijerink KM; Hackeng WM; Singhi AD; Heaphy CM; Brosens LA
J Pathol; 2022 Feb; 256(2):143-148. PubMed ID: 34750813
[TBL] [Abstract][Full Text] [Related]
17. A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.
Sadanandam A; Wullschleger S; Lyssiotis CA; Grötzinger C; Barbi S; Bersani S; Körner J; Wafy I; Mafficini A; Lawlor RT; Simbolo M; Asara JM; Bläker H; Cantley LC; Wiedenmann B; Scarpa A; Hanahan D
Cancer Discov; 2015 Dec; 5(12):1296-313. PubMed ID: 26446169
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic Neuroendocrine Tumors.
Salaria SN; Shi C
Surg Pathol Clin; 2016 Dec; 9(4):595-617. PubMed ID: 27926362
[TBL] [Abstract][Full Text] [Related]
19. Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential.
Camilli M; Papadimitriou K; Nogueira A; Incorvaia L; Galvano A; D'Antonio F; Ferri J; Santini D; Silvestris N; Russo A; Peeters M; Rolfo C
Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):471-478. PubMed ID: 29629846
[TBL] [Abstract][Full Text] [Related]
20. Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines.
Boora GK; Kanwar R; Kulkarni AA; Pleticha J; Ames M; Schroth G; Beutler AS; Banck MS
Cancer Genet; 2015; 208(7-8):374-81. PubMed ID: 26087898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
